Efficacy and safety of Hizentra®, a subcutaneous immune globulin, in Japanese patients with primary immunodeficiency diseases
Toshio Miyawaki(University of Toyama), Toshiro Hara, Hirokazu Kanegane(Tokyo Medical and Dental University), Tadashi Ariga(Tokai University), Shigeaki Nonoyama(National Defense Medical College), Martin Bexon(Bexon Clinical Consulting (United States)), Hidetoshi Takada, Midori Kobayashi(FIND), Masafumi Yamada(Hokkaido University Hospital), Kohsuke Imai(National Defense Medical College Hospital), Mikhail Rojavin(CSL (United States))
Cited by 0
Related Papers
The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome
|Cell|1993|824
Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma
|Cancer Cell|2021|607
Common Defects of ABCG2, a High-Capacity Urate Exporter, Cause Gout: A Function-Based Genetic Analysis in a Japanese Population
|Science Translational Medicine|2009|438